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Abstract: Glycosaminoglycans (GAGs) are found covalently attached to proteins, which create
conjugates known as proteoglycans. GAGs have remarkable biological activity as co-receptors
for a variety of growth factors, cytokines, and chemokines. The present study identifies the
key compositional differences between the GAGs isolated from whelk and mammalian GAGs.
This polysaccharide represents a new, previously undescribed GAG with cytotoxic activity on
cancer cells. Disaccharides were obtained by sample digestion with heparinases I, II, and III and
chondroitinase ABC. The resistant oligosaccharides from whelk GAGs treated with heparinase I, II,
and III and chondroitinase ABC were retained by the filter due to their larger size. Disaccharide
analysis was performed using Glycan Reduction Isotope Labeling (GRIL LCQ-MS). The amounts of
filter-retained fragments, as assessed by monosaccharides analysis, suggested that a proportion of
the whelk GAG chains remained resistant to the enzymes used in the disaccharide analysis. Thus,
the proportions of individual disaccharide produced in this analysis may not truly represent the
overall proportions of disaccharide types within the intact whelk GAGs chain. However, they do
serve as important descriptors for the classification and make-up of the anti-cancer GAGs chains.
Furthermore, these data represent clear evidence of the compositional differences between whelk
GAGs and commercial mammalian GAGs.
Keywords: glycosaminoglycans; marine mollusca; anti-cancer, anti-proliferation; heparan sulphate
1. Introduction
Glycosaminoglycans (GAGs) are found covalently attached to proteins, creating conjugates known
as proteoglycans. GAGs are linear glycan chains composed of a repetitive structure of disaccharide
units of uronic acid and glucosamine. Initially, it was thought that GAGs only existed in mammals.
However, they are found in a wide variety of organisms, including fishes, insects, fungi, yeast, and
bacteria. It is a particularly rich component in the muscle of shellfish [1]. Glycosaminoglycans
have remarkable biological activities as co-receptors for a variety of growth factors, cytokines,
and chemokines [2]. In addition, sulphated polysaccharides have been recognized to possess various
biological properties, including anticoagulation, antiviral effects, and immunomodulatory activity that
might find relevance in nutraceutical/functional foods, cosmetic/cosmeceutical and pharmaceutical
applications [3]. Furthermore, the biological function of proteoglycans includes the regulation of
cell proliferation through the interaction of the GAGs chains in proteoglycans with proteins, such as
growth factors and their receptors [4].
There are many types of GAG: hyaluronic acid (HA), chondroitin sulphate (CS), dermatan
sulphate (DS), keratan sulphate (KS), heparin (Hep), and—the most widely studied—heparan sulphate
(HS). The main differences between the family members are the position and configuration of their
glycoside linkages, the amount and location of their sulphate substituents, and their monosaccharide
composition. Some of these species have a very simple structure, such as hyaluronic acid, while others,
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such as CS, DS, Hep and HS, contain extensive blocks of modified disaccharide units with complex
sulphation patterns that appear to be under tight biosynthetic control [5].
Heparin and HS have been intensively studied due to their ability to bind many proteins that
regulate a variety of important biological processes [6].
Heparan sulphates are comprised of alternating glucosamine and uronic acid residues.
The disaccharide units in the heparin chain are extensively modified, which differs from the HS
chain. In HS biosynthesis and modification, the selected GlcNAc residues likely undergo the
N-deacetylation/N-sulfation modification. Thus, the HS chain appears as blocks of unmodified
sequences (N-acetyl NAc-domain), which are separated by highly modified residues of N-sulphate
(NS-domain) [7].
However, in heparin, the chain essentially contains N-sulphate (NS-domain) interrupted by
N-acetyl (NAc-domain). During the modification reactions, three types of domains are likely to be
generated. First, the unmodified N-acetylated regions (NA-domain) with glucuronic acid (GlcA) units,
which are present in small amounts in the predominant disaccharide units in HS. The second type
are adjacent N-sulphated regions with 2-O- and 6-O-sulphated iduronic acid (IdoA) and glucosamine
residues respectively in the NS-domain. Finally, alternating regions of N-sulphated and N-acetylated
disaccharides domain appear in HS chains [8,9].
GAGs have been isolated from various tissues obtained from a large number of animal species,
including both vertebrates and invertebrates [10]. Heparin has only been found in one invertebrate
phylum, the Mollusca, and it often constitutes up to 90% of the total GAG content of these organisms.
The heparin that has been isolated from various molluscs was found to be structurally different from
human heparin and pharmaceutical heparin [11,12].
Nowadays, there is an interest in developing potent therapeutic agents from non-mammalian
GAG sources. Hence, these novel GAGs provide possible alternative therapeutic agents for treating
diseases such as cancer [13,14].
In this study, we isolated the complex polysaccharides from the soft body of whelk. The main
differences in the composition of these GAGs and mammalian GAGs occur due to the abundance of
disaccharides and different sulphation patterns within the glycan chain. This whelk polysaccharide
has a high anti-cancer activity and is able to inhibit the growth of several cancer cell lines, which
have been tested in vitro. The anti-proliferative activity of these GAGs on triple negative breast
cancer (TNBC) cell lines is reported in this study. Moreover, the anti-proliferation activity of GAGs
on ER+ cells, such as MCF-7 and SKBR-3, was evaluated, and significant inhibition was reported
(data not shown). The biological activity of these highly sulphated GAGs was strongly connected to
their unique composition and degree of sulphation, which proved to be different from mammalian
glycosaminoglycans, with no anti-cancer activity.
2. Results
2.1. Glycan Reductive Isotope Labelling (GRIL) Analysis of GAGs Disaccharides
Disaccharide analysis was performed using a GRIL LCQ-MS analysis protocol for GAG
disaccharides [15]. A new shorthand nomenclature for the disaccharide subunit structure of GAGs was
used in the present study according to Lu et al. [16]. The results from the disaccharide analysis of the
CS and HS components of the whelk GAG chain are shown in Tables 1 and 2, which show significant
differences in the disaccharide composition and overall sulphate content in comparison to commercial
porcine HS and CS (Tables 3 and 4). ∆HexA2S-GlcNS and ∆HexA2SGlcNS6S constituted 92–93%
of the N-sulphated disaccharides found in CK-1, compared with 61–62% present in commercial HS,
in terms of individual disaccharide, which suggested that ∆HexA2S-GlcNS and ∆HexA2SGlcNS6S
were enriched in the whelk GAG sample.
There is a notable difference in the disaccharide ∆HexA2S-GlcNS, which is the most abundant
disaccharide in the whelk GAGs (43.15%) and the second-least abundant in the porcine heparin (0.9%).
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Disaccharide analysis confirmed the presence of CS chains in the whelk samples CK-1, CK-2 and CK-3,
and the amount of individual CS disaccharide was determined by GRIL LCQ-MS GAGs disaccharide
analysis. Chondroitinase ABC degradation of the whelk GAG sample confirmed the presence of
susceptible linkages as a result of the presence of CS in the anti-cancer GAG samples. The MTT assay
of whelk GAGs treated with chondroitinase ABC showed no decrease in anti-cancer activity. This is in
marked contrast to the whelk GAGs treated with heparinases I, II, and III, which showed a significant
loss of anti-cancer activity after sample degradation and incubation with triple negative breast cancer
MDA-MB-468 and MDA-MB-231 cell lines.
Table 1. Disaccharide analysis of crude whelk GAGs. Data are presented as an estimated percentage of
each HS disaccharide produced by heparinases I, II, and III digestion.
Disaccharides from Heparinases
I, II, and III Digestion of Intact
Whelk GAGs
% Mole in CK-1
(1M NaCl)
Fraction
% Mole in CK-2
(2M NaCl)
Fraction
% Mole in CK-3
(3M NaCl)
Fraction
% Mole in
Commercial
Porcine HS
D0H0 0.00 0.00 0.00 0.00
D0A0 1.70 1.91 10.10 28.35
D0H6 0.12 0.00 0.00 0.13
D2H0 0.23 0.00 0.00 0.03
D0S0 1.85 1.42 7.28 12.39
D0A6 2.19 1.63 1.48 10.55
D2A0 0.79 0.69 0.09 1.33
D2H6 0.36 0.06 0.24 0.41
D0S6 8.83 18.90 16.17 11.21
D0S0 43.15 35.28 28.93 8.81
D2A6 4.18 3.45 0.08 0.98
D2S6 36.60 36.66 35.62 25.81
Table 2. Disaccharide analysis of crude whelk GAGs. Data are presented as an estimated percentage of
each CS disaccharide produced by chondroitinase ABC.
Disaccharides from
Chondroitinase ABC
Digestion of Intact
Whelk GAGs
% Mole in CK-1
(1M NaCl)
Fraction
% Mole in CK-2
(2M NaCl)
Fraction
% Mole in CK-3
(3M NaCl)
Fraction
% Mole in
Commercial
Porcine CS
D0a0 4.43 4.02 4.95 3.83
D0a4/D2a0 35.36 20.53 12.21 59.77
D0a6 2.00 2.81 0.67 34.71
D2a4 0.02 0.00 0.00 0.16
D2a0 0.59 1.43 77.74 0.04
D0a10 57.60 71.22 4.42 1.39
D2a10 0.00 0.00 0.00 0.00
Table 3. Sulphation types in HS disaccharides in fractions CK-1, CK-2, and CK-3 in whelk GAGs.
Type of Sulphation HS-CK-1 HS-CK-2 HS-CK-3 Standard Mammalian HS
%Unsulphated 1.70 1.91 10.10 28.35
%N-SO3 90.44 92.26 88.01 58.21
%2-O-SO3 85.31 76.15 64.96 37.37
%6-O-SO3 52.28 60.71 53.59 49.09
Average SO3 per disaccharide 2.28 2.29 2.07 1.45
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Table 4. Sulphation types in CS disaccharides in fractions CK-1, CK-2, and CK-3 in whelk GAGs.
Type of Sulphating CS-CK-1 CS-CK-2 CS-CK-3 Standard Mammalian CS
%Unsulphated 4.43 4.02 4.95 3.83
%2-O-SO3 0.61 1.43 77.74 0.30
%4-O-SO3 92.98 91.74 16.63 61.42
%6-O-SO3 60.18 75.45 82.84 36.24
Average SO3 per disaccharide 1.54 1.69 1.77 0.98
2.2. Monosaccharide Quantitative Analysis of GAGs’ Filter-Fraction Fragments
The analysis of monosaccharides for the filter-retained fragment of CK-1, CK-2 and CK-3 was
performed in order to determine the monosaccharides that remained in the mixture. The data in
Figures 1 and 2 show the monosaccharide compositions for CK-1, CK-2 and CK-3 filter-retained
fragments from whelk GAGs in comparison to the standard monosaccharide uronic acid (MonoUA-Std)
(Figure 3). The amount of filter-retained material, as assessed by monosaccharide analysis, suggested
that a proportion of the whelk GAG chain remained resistant to the enzymes used in the disaccharide
analysis. Furthermore, the monosaccharide analysis suggested considerably lower levels of IdoA
in whelk GAGs when compared to mammalian GAGs. This suggests significant differences in
the epimerization from glucuronic acid GlcA to iduronic acid IdoA in the synthesis of whelk and
mammalian GAGs. The presence of considerable numbers of O-sulphated GlcA in whelk GAGs may
be linked to the difference in anti-cancer activity.
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2.3. Cytotoxic Activity of Intact GAGs and Their Fragments on Triple Negative Breast Cancer
An experiment was carried ut to assess the impact of the crude whelk extracts and their
fragments o the cell proliferation in triple negative breast cancer. Whelk GAG crude extract has
significant inhibitory activity on the t iple n gative breast cancer MDA-MB-231 and MDA-MB-468
cell lines. Remarkable EC50 values were observed in both cell lines, and were approxi ately
3.48 ± 0.02 µg mL and 2.76 ± 0.01 µg/mL, respectively. The bioactivity of whelk GAGs a d
omm rcial mammalian HS/CS on triple n gative breast canc r cell lines were screene under two
conditions: cells treated with rude whelk GAGs; and cell treate with the w elk GAGs following
digestion by heparinases I, II, and III, and chondroitinase ABC. The resul s indicated no inhibition of
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growth in TNBC from commercial mammalian HS and CS, either before or after enzymatic degradation
(Figure 4). In contrast, significant inhibition was observed following treatment with whelk GAG extract
before and after enzymatic degradation with HS and CS lyases (Table 5). Nevertheless, the biological
activity of the fragments generated from heparinases I, II, and III was slightly reduced in comparison
to the fragments generated from chondroitinase ABC.
Table 5. EC50 values of the effect of whelk GAGs fragments produced by heparinases I, II, and III and
chondroitinase ABC on TNBC cell lines.
- Cell Line
EC50 µg/mL
Crude Whelk
GAGs
EC50 µg/mL
Whelk GAGs +
Heparinase I
EC50 µg/mL
Whelk GAGs +
Heparinase II
EC50 µg/mL
Whelk GAGs +
Heparinase III
EC50 µg/mL
Whelk GAGs +
Heparinase I,
II, and III
EC50 µg/mL
Whelk GAGs +
Chondroitinase
ABC
1 MDA-MB-468 2.80 ± 0.02 2.60 ± 0.01 42.30 ± 0.02 37.90 ± 0.03 33.20 ± 0.01 3.00 ± 0.01
2 MDA-MB-231 3.50 ± 0.01 14.00 ± 0.01 24.90 ± 0.03 26.00 ± 0.03 27.60 ± 0.02 4.60 ± 0.01
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Figure 4. Anti-proliferation activity of crude whelk GAG extract compared to the activity of commercial
mammalian HS and CS GAGs before and after enzymatic degradation. Panels A1 and B1: shows the
effect of whelk GAGs on the MDA-MB-231 cell line. Panels A2 and B2: shows the effect of whelk
GAGs on the MDA-MB-468 cell line. The data represent the percentage of viable cells for sample size
(n = 3) as mean ± SD. Cells wer cultured in monolayers and maintained at 37 ◦C in a humidified 5%
CO2 tmosphere. The cytotoxicity assay was performed using the MTT colorimetric assay.
2.4. Identification of the GAGs’ Active Fractions for Triple Negative Breast Cancer
The crude extraction from whelk GAGs was analyzed using a variety of analytical techniques
in order to identify the structure of the GAGs in relation to the active part of the polymer that is
responsible for their activity on triple negative breast cancer cell lines. The inhibitory activity was
retained by the filter-retained fragments (R) that did not pass through the centrifugal filtration device
following the enzymatic degradation of all fractions obtained from whelk GAGs using ion-exchange
chromatography. An equal amount (100 µg/mL) of flow-through (FT) and filter-retained (R) fragments
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from fractions (CK-1, CK-2 and CK-3) were incubated with both cell lines for five days at 37 ◦C and 5%
CO2. The cells were cultured in a monolayer in 96-well plates and incubated for 24 h, at which point
the medium was changed and a fresh medium was added to all wells. Cytotoxic activity was obtained
using the MTT assay. The data were validated using the GraphPad Prism 5.0 software. The results
shown in Figure 5 demonstrate the activity of whelk GAGs that had been degraded by heparinases I,
II, and III or chondroitinase ABC and passed through the filter. These FT fragments are more likely to
contain disaccharides or oligosaccharides that are smaller in size than the pore size of the filter, and
are therefore capable of passing through the device. The results shown in panel A1 and panel B1 of
Figure 5 indicate no effect of the FT fragments that were treated with heparinases I, II, and III on either
the MDA-MB-231 or MDA-MB-468 cell lines. Moreover, no inhibitory activity on either cell line was
seen for the FT fragments from chondroitinase ABC treatment, as shown in Panels A3 and B3. On the
other hand, significant inhibitory activity on the cell lines was observed in the filter-retained fragments
(R) of heparinases I, II, and III and chondroitinase ABC.
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fragment was noticed, which might be associated with structural heterogeneity in these GAGs, or be 
Figure 5. Anti-proliferation activity of whelk GAGs fractions of CK-1, CK-2 and CK-3 before and
after enzymatic degradation on triple negative breast cancer cell lines. Panel A: Inhibition activity
of FT and R fractions from heparinases I, II, and III and chondroitinase ABC fragments on the
MDA-MB-231 cell line. A1 shows the activity of FT fragments from a 10K filter of heparinases I,
II, and III degradation of whelk GAGs. A2 shows the activity of R fragments from a 10K filter of
heparinases I, II, and III degradation of whelk GAGs. A3 shows the activity of FT fragments from a 10K
filter of chondroitinase ABC degradation of whelk GAGs. A4 shows the activity of R fragments from
a 10K filter of chondroitinase ABC degradation of whelk GAGs for each fraction of CK-1, CK-2 and
CK-3 from the anion-exchange chromatography. Panel B: Inhibition activity of FT and R fragments
from heparinases I, II, and III and chondroitinase ABC on the MDA-MB-468 cell line. B1 shows the
inhibitory activity of FT fragments from a 10K filter of heparinases I, II, and III degradation of whelk
GAGs. B2 shows the inhibitory activity of R fragments from a 10K filter of heparinases I, II, and III
degradation of whelk GAGs. B3 sh ws the inhibitory activity of FT fragment from a 10K filter of
chondroitinase ABC degra atio of whelk GAGs. B4 shows t e inhibitory activity of the R fragment
from a 10K filter of chondroitinase ABC degradation of whelk GAGs fo each fraction of CK-1, CK-2
and CK-3 from the anion-exchange chromatogr phy. The data represent the percentage of viable c lls
for sample size (n = 3) as mean ± SD. Cells were cultured i monolayers and maintained at 37 ◦C in a
humidified 5% CO2 atmosphere. Cytotoxicity assay was performed using the MTT colorimet ic assay.
3. Discussion
Extraction and subsequent purification of GAGs from whelk showed that the soft tissue contained
a large amount of GAGs. These GAGs contained highly sulphated polysaccharides compared to
porcine mucosal heparin or CS. Disaccharide analysis showed the abundance of different disaccharide
units present in whelk GAGs and sulphation patterns that differed from mammalian GAGs.
The partial resistance of this polysaccharide toward heparinases I, II and III suggested that this
polysaccharide had a different composition to the heparin and HS from mammalian tissues [17]. In this
study, small amounts of GlcA were observed, and no presence of IdoA from the filter-retained fragment
was noticed, which might be associated with structural heterogeneity in these GAGs, or be due to a
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unique modification in the incomplete epimerization of GlcA to IdoA. This might be the main reason
for their anti-cancer activity.
Ion-exchange chromatography enabled the fractionation of the GAG samples according to their
net charged groups using the stepwise addition of sodium chloride with three different buffer strengths.
The results show that approximately 90% of the total sample applied to the column was eluted with
1M NaCl, which was followed by smaller amounts of GAGs eluted with 2M and 3M NaCl. The results
show the abundance of different disaccharide units present in whelk GAGs, along with their sulphation
patterns, which differ significantly from mammalian GAGs, for the first time. Reasonable amounts of
GAGs were detected from the filter-retained fragment of the Nanosep centrifugal tube containing the
omega membrane (10K filter Eppendorf tube), which could also be the result of incomplete digestion
by heparinases I, II, and III and chondroitinase ABC. The filter-retained fragments showed cytotoxicity
toward the cancer cell lines while the flow-through was inactive. This finding was unexpected and
suggested that the filter-retained fragments might contain the key heparinase-resistant sequences that
might be responsible for the biological activity, and as such, elucidating their structure is important for
future studies.
The presence of this polysaccharide with a simple but unique sequence raises questions about
their biological activities, including their roles in cancer treatment. The administration of some
glycosides leads to many cellular changes, including reduction of cancer cell adhesion, suppression of
cell migration and tube formation in cancer cells, suppression of angiogenesis, inhibition of cell
proliferation and tumor invasion. As a result, growth inhibition of tumors occurs in vitro and
in vivo [18].
Whelk CS-GAGs may have anti-cancer activity; but the chondroitinase ABC treatment followed
by the MTT assay did not support this assumption. Fucosylated CS may be present in the sample and
this could conceivably be resistant to chondroitinase ABC. However, the digestion of whelk GAGs
with heparinase and anti-cancer assessment of the fragments still suggests that a HS is still the primary
target in the search for the active components within the whelk GAG sample.
4. Materials and Methods
Porcine mucosal heparin, heparan sulphate and chondroitin sulphate were purchased from
Celsus (Cincinnati, OH, USA). Heparinases I, II, and III used in the large-scale depolymerization were
obtained from Grampian Enzymes (Aberdeen, UK). Chondroitinase ABC was from IBEX (Montreal,
QC, Canada). All other reagents used were of analytical grade. The alkaline protease mixture, alcalase,
was from Novo (New York, NY, USA). Spectrapore dialysis membranes with a molecular cut-off weight
of 1000 Da were from Spectrum Medical (Los Angeles, CA, USA). A small Polyprep column from
BioRad (Watford, Hertfordshire, UK) was packed with 500 µL of Diethylaminoethyl DEAE Sephacel
(GE-Healthcare, Visalia, CA, USA).
4.1. Extraction of Whelk GAGs
Crude GAGs were extracted as a white powder from the shellfish common whelk (Buccinum
undatum), which was obtained from a local fish market in Manchester (the original collection place
was the Irish Sea). The shell was removed and 200 g of the soft body was defatted using 100% acetone
for 72 h. The sample was dried at room temperature for 48 h. A blender was used to convert the
fat-free dried whelk into in to a powder. Following the extraction method from Kim, et al. [19], 4 g
of the powder was suspended in 40 mL of 0.05 M of sodium carbonate buffer at a pH of 9.2, before
2 mL of alcalase enzyme was added to degrade protein and release GAG chain. This step takes
approximately 48 h at 60 ◦C, with constant agitation at 200 rpm. The mixture was cooled at 4 ◦C
before 5% (w/v) trichloroacetic acid was added to the sample and mixed to precipitate peptides.
After 10 min, the mixture was centrifuged at 8000× g rpm for 20 min. Three volumes of 5% (w/v)
potassium acetate in ethanol were added to one volume of supernatant, and the solution was stored
at 4 ◦C overnight before being centrifuged for 30 min at 8000× g rpm. The precipitate, which was
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approximately 1 g, was dissolved in 40 mL of 0.2 M of NaCl solution and centrifuged at 8000× g rpm
for 30 min with the supernatant subsequently discarded. Cetylpyridinium chloride (0.5 mL of 5% (w/v)
solution) was added to the supernatant followed by centrifugation to recover the precipitate, which
was subsequently dissolved in 10 mL of 2.5 M of NaCl. Finally, 5 volumes of ethanol were added
followed by centrifugation for 30 min at 10,000× g rpm. After this, the precipitate was collected and
dialyzed against water for 72 h. The water was changed twice daily, before the sample was lyophilized
to obtain a white powder containing approximately 2.0 mg of crude GAGs.
4.2. Anion-Exchange of Intact GAGs
A small polyprep column from BioRad was packed with 500 µL of DEAE-Sephacel (GE-Healthcare)
and the bed was calibrated with 5 mL of diethylaminoethyl DEAE pre-wash buffer (50 mM NaOAc/
150 mM NaCl with 0.1% Triton X-100 at a pH of 6.0). A total of 1 mg of crude GAGs was dissolved
in 500 µL of deionized water, with 250 µL of this solution was loaded onto the column. After this,
the column was washed with 5 mL of DEAE washing buffer (50 mM NaOAc/150 mM NaCl with at
a pH of 6.0). The GAGs were eluted by adding 2.5 mL of DEAE elution buffers (1–50 mM NaOAc/
1M NaCl pH 6.0, 2–50 mM NaOAc/2M NaCl pH 6.0 and 3–50 mM NaOAc/3M NaCl pH 6.0).
Each fraction was collected separately. All samples had salt removed using the PD-10 column.
4.3. PD-10 De-Salting Technique
The PD-10 column from GE-Healthcare was used for desalting and buffer exchange. The sample
preparation in the range of 1.0–2.5 mL by gravity flow was carried out. The desalting capacity
was greater than 90%, and the recovery rate was in the range of 70–95%. The bed dimensions were
14.5 × 50 mm, and the column was prepacked with Sephadex G-25 medium. The column was prepared
by washing 6 times with 10% ethanol, before 1 mL of sample was loaded and washed with 2.5 mL of
10% ethanol. The first 2.5 mL of eluted buffer was discarded as it is the void volume of the column.
The next 3.5 mL of 10% ethanol were collected and lyophilized.
4.4. Enzymatic Degradation of Ion-Exchange Fractions
A total of 100 µL (10%) of each fraction (CK-1, CK-2, and CK-3) was incubated with a mixture of
heparinases (30 mU Hep I + 16 mU Hep II+ 16 mU Hep III) and chondroitinase ABC (1.5 µL of 5 IU/µL
AC + 1.5 µL of 5 IU/µL B) for 24 h. The same protocol was applied to the standard commercial porcine
HS and CS.
All samples were fractionated using a 10,000 MWCO filter (Pall Laborotary/Westborough, MA,
USA) (Nanosep centrifugal with an omega membrane). The filter contains the omega membrane
that has low protein-binding, modified polyethersulfone on a polyethylene substrate. The filtrate
receiver is polypropylene, for rapid purification, separation of mixture and sample fractionation.
The membrane pore size is less than 5 nm, and the membrane is able to fractionate biomolecules with
a range of 30–90 K molecular weight. To remove the enzyme and undigested GAG chain, the samples
were centrifuged at 14,000× g for 20 min. The flow-through fragments (the material in the bottom
of the Eppendorf tubes) were collected mainly as disaccharides and lyophilized for further analysis.
The filter-retained fragments (the material on the top of the filter in the Eppendorf tubes), which was
considered to be undigested material, was also dried for further investigation.
4.5. Isotopic Aniline Tagging for GAG Disaccharide Analysis by Mass Spectrometry (GRIL-Glycan Reductive
Isotope Labeling)
Isotopic aniline tagging for GAG disaccharide analysis by mass spectrometry was used following
the protocol described by Lawrence et al. First, 15 µL of 12C6 isotope aniline and 15 µL of 1 M of 95%
sodium cyanoborohydride/sodium (NaCNBH3) (Sigma-Aldrich, Poole, UK), was freshly prepared
in dimethyl sulfoxide: acetic acid (65:35 v/v), which was added to each GAG fraction from the
ion-exchange chromatography (CK-1, CK-2 and CK-3); after this, 8 pmol of the HS and CS standard
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disaccharides were used and mixed with the tagging buffer above the tagging buffer. Reactions
were carried out at 37 ◦C for 16 h, before the product was dried in a centrifugal evaporator. After the
complete sample was tagged with the 12C6 aniline isotope label, 17 µL of the LC-MS-grade water (water,
8 mM acetic acid, 5 mM DBA) was added to each fraction (CK-1, CK-2 and CK-3), which was mixed
gently to produce a homogenate mixture. The sample was centrifuged at 14,000×g for 7 min, before
5 µL was taken and added to LC-MS vials and spiked with 2 µL of 8 pmol internal 13C6 aniline isotope
tag. A total of 1 µL of 10× GRIL buffer and 2 µL of LC-MS water were added to bring the mixture up
to the total volume of 10 µL, with only 4 µL injected into the system. A quaternary high-performance
liquid chromatography (Thermo-Finnigan, San Jose, CA, USA) was used for disaccharides analyses.
Aniline isotopic disaccharides and non-isotopic disaccharides were separated on a C18 reversed-phase
column (0.46 cm × 25 cm, Vydac) with the ion-pairing agent dibutylamine (DBA, Sigma-Aldrich).
The gradient system used was 100% buffer A (8 mM acetic acid, 5 mM DBA) for 10 min, 17% buffer
B (70% methanol, 8 mM acetic acid, 5 mM DBA) for 15 min, 32% buffer B for 15 min, 40% buffer B
for 15 min, 60% buffer B for 15 min, 100% buffer B for 10 min, and 100% buffer A for 10 min. Most
disaccharides eluted in the 60% buffer B (42% methanol) were further analyzed using the classic
quadrupole ion trap mass spectrometer equipped with an electrospray ionization source used for
sample ionization and detection. Ions of interest were collected in negative ion mode. The capillary
temperature and spray voltage were maintained at 140 ◦C and 4.75 kV to decrease the in-source
fragmentation of sulphated disaccharides.
4.6. Quantitative Analysis of Monosaccharides by HPAEC-PAD
The samples containing 1 mg of crude GAGs were dissolved in 1 mL of deionized water, and a
100 µL (10% GAGs) aliquot was treated with 100 µL of 4N trifluoroacetic acid and 4N TFA (prepared
by adding 2.40 mL deionized water to 1.00 mL of 13.5 M TFA, providing a stock with 4N TFA) at
100 ◦C for 4–6 h to cleave all glycosidic linkages, including uronic acids. Following hydrolysis, sample
tubes were removed from the heating block and allowed to cool to room temperature. The samples
were centrifuged at 27,000×g rpm for 3 min to remove any condensation on the side of the tube. Acid
was evaporated by dry nitrogen flush for 10 min, and we repeated co-evaporation with 70 µL of 50%
isopropanol to remove the acid completely. Finally, the samples were dissolved in 100 µL deionized
water and centrifuged, before being analyzed by HPAEC-PAD (Thermo Scientific, San Diego, CA,
USA) using a CarboPac PA-1 column with dimensions 4 mm × 250 mm, 4 mm, with a 4 mm × 50 mm
Guard. The solvents used were A: Water, and B: 100 mM sodium hydroxide (NaOH) with 5 mM
(sodium acetate trihydrate) NaOAc·3H2O. The initial condition of 16% B at 1.0 mL/min was applied,
a pulsed amperometric detector (PAD) was used in this system. In PAD applications, the electrode is
automatically cleaned and prepared for detection by each cycle of the programmed series of potentials
(i.e., the waveform), thereby minimizing electrode fouling by oxidation products of the analyte, thus
maintaining a consistent response. Monosaccharide standards were treated in parallel and used for
calibration of the HPAEC-PAD response.
4.7. Routine Cell Culture
Triple negative breast cancer MDA-MB-468 and MDA-MB-231 cell lines were cultured as
monolayers. Cells were maintained at 37 ◦C in a humidified 5% CO2 atmosphere. The complete
growth medium used to culture the adherent cells were contains Dulbecco’s Modified Eagle’s
Medium (DMEM-w/1, g/L glucose without L-glutamine/ BE12-707F) from Lonza, to which 10% FBS
(500 mL-FB-1090/500) and 2 mM L-glutamine (100 mL-XC-T1715/100) from Lab Tech (London, UK)
were added. Cells were grown in tissue culture flasks T-25 (Vented Filter Cap, TC-Treated-Green-30 ×
10-CC7682-4825) from the Star lab to approximately 70–80% confluence, before the media were removed
and the cells were washed with warm PBS at a pH of 7.4 (10010023-Thermo fisher scientific, London,
UK) prior to trypsinization. The cells were detached by incubation in 1 mL of 1× trypsin-EDTA solution
at 37 ◦C for 5–10 min (Trypsin 0.25%—and EDTA in HBSS without Calcium or Magnesium with phenol
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red 100 mL of CC-5012) from Lonza (Cambridge, UK). Cells were collected by centrifugation at 1500× g
rpm for 5 min and resuspended into fresh medium. The medium was renewed 3 times per week from
24 h after each seeding.
4.8. MTT Colorimetric Assay
The healthy cells, which had been sub-cultured at least once and subsequently reached 70–80%
confluence, were used for the MTT assay. A total of 3000 cells per 100 µL per well were used. After this,
the cells were incubated at a temperature of 37 ◦C with 5% CO2. After 24 h of incubation, the cells
were examined under the microscope to ensure that there were no signs of contamination and the
cells were healthy. Subsequently, 100 µg/100 µL extracts of whelk GAGs, filtered by a 0.2 µm sterile
filter, was added into the corresponding wells. The concentration of the extract was prepared in serial
dilutions according to the microplate template, which started with a negative control in the first well
(row A) until it reached the highest concentration in row H. The assay was performed in triplicate.
After this, the plates were incubated to allow the cell proliferation with or without the presence of the
whelk GAGs. After 96 h of incubation, the plates were taken out of the incubator and 50 µL of the
MTT solution at a concentration of 5 mg/mL was added to each well. The plates were then kept in
the incubator for the next 3–4 h until the purple crystals of formazan salt were produced. After this,
the medium was removed through gentle aspiration of the liquid, leaving the crystals at the bottom of
the wells. Subsequently, 200 µL of DMSO was added to each well to dissolve the formazan crystal,
before the absorbance of the formazan solution in the micro plate was measured at 450 nm (OD1),
with a reference wavelength at 690 nm (OD2).
5. Calculation of EC50 Values
The data were analyzed using GraphPad prism 5.0 (GraphPad Software, San Diego, CA, USA).
EC50 values were determined using a non-linear regression to fit a dose response curve to the data
after transforming the drug concentrations to log values on X. The response was normalized and was
represented as Y values.
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